Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info

Novartis has revised labeling for the irritable bowel syndrome therapy Zelnorm to include the risk of developing severe diarrhea and ischemic colitis, FDA says in a 1"Talk Paper" issued April 28